Ludvik, B., et al., Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
Different concentrations of ligand in stimulation buffer were added and the stimulation lasted for 40 min at RT
This is done for two reasons
Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects
For a 200-pound person, that would be 30-40 pounds
Healthier populations lead to fewer sick days, higher workforce participation, and reduced long-term healthcare costs